Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer

Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer

Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first‐line treatment option for extensive‐stage small cell lung cancer (ES‐SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first‐line chemot...

Full description

Bibliographic Details
Main Authors: Nobutaka Kataoka, Yusuke Kunimatsu, Yusuke Tachibana, Takumi Sugimoto, Izumi Sato, Nozomi Tani, Yuri Ogura, Kazuki Hirose, Takayuki Takeda
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Thoracic Cancer
Subjects:
Atezolizumab
carboplatin
etoposide
retreatment
small cell lung carcinoma
Online Access:https://doi.org/10.1111/1759-7714.13588

Internet

https://doi.org/10.1111/1759-7714.13588

Similar Items